AGORACOM News Flash

AGORACOM CONFERENCE UPDATE

12 More Companies Added To Schedule For Dec 3 & 4. (See Schedule)
Keynote Speakers Include Peter Grandich, Eric Coffin (See Speakers)
Workshop Presentations Added To Thursday Schedule
Investors from over 45 Countries Have Visited
Conference Begins 2 Weeks From Today!

Looking forward to seeing all of you there gang. Registration is free for investors. AGORACOM Members register with just one click. Non-members takes less than 60 seconds. Register here (see form on right hand side)

Message: HAE & Angiotech Enter License, Distribution and Supply Agreements ........

Cooky

Rank: [?]

President

Points: [?]

12546

Rating: [?]

Votes: 71 Score: 3.5

Currently 3.5/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

HAE & Angiotech Enter License, Distribution and Supply Agreements ........

posted on Jul 03, 09 11:19PM

Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacure's All-Human Fibrin Sealant and Thrombin Products

Press Release
Source: HAEMACURE CORPORATION
On Wednesday June 3, 2009, 10:47 am EDT

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPI, TSX: ANP), please visit its website at www.angiotech.com.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

For further information

Haemacure Corporation: Joseph Galli, Chairman and CEO, (514) 990-7074, jgalli@haemacure.ca
Gilles Lemieux, Secretary, (514) 282-3350 ext. 22, ir@haemacure.ca
www.haemacure.com